Stock PMED PEPTONIC MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PEPTONIC medical AB

Equities

PMED

SE0005962206

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 23:00:00 30/01/2024 GMT 		5-day change 1st Jan Change
0.06 SEK -.--% Intraday chart for PEPTONIC medical AB -.--% +3.45%
05-31 Peptonic Medical Secures European Patent for Treatment of Vulvodynia MT
05-31 Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Peptonic Medical: Peptonic announces outcome in the rights issue and the directed issue
PU
Peptonic announces outcome in the rights issue and the directed issue
AQ
Peptonic Medical provides an operational update after the first 120 days with new CEO
AQ
Last day of trading with the unit rights in Peptonic
AQ
Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch.
AQ
The subscription period in Peptonic's rights issue of units starts today
AQ
Peptonic publishes prospectus in connection with rights issue of units
AQ
PEPTONIC medical : Interim report Jan-March 2024
PU
Peptonic Medical AB Announces Organizational Changes
AQ
The board of Peptonic has decided to carry out a directed issue of units consisting of shares and warrants of series TO5
AQ
PEPTONIC medical : Updated year end report Jan-Dec 2023
PU
PEPTONIC medical : Year end report Jan Dec 2023
PU
Jenni Björnulfson appointed as new CFO of Peptonic Medical
AQ
Warrants of series TO4 were subscribed to approximately 1.80 percent and Peptonic receives approximately SEK 0.1 million
AQ
The last day of trading with the warrants of series TO4 in PEPTONIC medical AB is today, April 26, 2024
AQ
The board of Peptonic resolves, subject to approval of the general meeting, on a rights issue of units of approximately SEK 61.4 million
AQ
The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024
AQ
Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women
AQ
Peptonic Medical AB strengthens its position in Europe through an exclusive distribution agreement for VagiVital and Vernivia in the Benelux region
AQ
Peptonic Medical AB announces that CFO is leaving for new challenges and that the company's financial infrastructure is strengthened
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PMED Stock
  4. News PEPTONIC medical AB
  5. Press Releases